Patient-based drug discovery's latest news
Meet us at Conferences and Partnerings
We’re excited to be present at a series of dynamic conferences, partnering events, and investor meetings throughout the rest of the year. If you're attending too, don’t hesitate...
New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features
In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K...
New publication on morphological map of under- and overexpression of genes in human cells
As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich...
New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons
In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA...
We are thrilled to announce the arrival of our new Chief Operating Officer!
Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the...
Join Ksilink at BIO Partnering @ JPM Week 2025!
We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San...
Ksilink Advances PMDS Research and Disease Modelling
Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into...
02.04.2024: World Autism Awareness Day
Link to photo source (UN) At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid...
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease Ksilink, in collaboration with researchers from the University of Chieti in Italy, has published...
